
See discussions, stats, and author profiles for this publication at: https://www.researchgate.net/publication/369256139

The effects of purslane consumption on glycemic control and oxidative stress: A systematic review and dose-response meta- analysis

Article *in* Food Science & Nutrition · March 2023 DOI: 10.1002/fsn3.3311



systematic review and meta-analysis View project

THE EFFECT OF MOMORDICA CHARANTIA ON GLYCEMIC CONTROL IN TYPE 2 DIABETIC PATIENT View project

REVIEW

The effects of purslane consumption on glycemic control and oxidative stress: A systematic review and dose-response metaanalysis

Naser Jafari ¹ Nargeskhatoon Shoaibinobarian ² Azadeh Dehghani ³
Amirhosein Rad ⁴ Seyedeh Nooshan Mirmohammadali ⁵ Mohammad Javad Alaeian ⁶
Yasaman Hamedi ⁷ Mohamad Zamani ⁸ Mohammad Ali Goudarzi ⁹ Omid Asbaghi ¹⁰ 💿

¹University of Applied Science and Technology - Allameh Tabarsi Center, Tehran, Iran

Revised: 17 January 2023

⁵Department of Food, Nutrition, Dietetics and Health, Kansas State University, Manhattan, Kansas, USA

⁶MD graduated from Shahid Beheshti University of Medical sciences, Tehran, Iran

⁷Department of Physical Education, Central Tehran Branch, Islamic Azad University, Tehran, Iran

⁸Department of Clinical Nutrition, School of Nutritional Sciences and Dietetics, Tehran University of Medical Sciences, Tehran, Iran

⁹Shahrekord Branch, Islamic Azad University, Shahrekord, Iran

¹⁰Cancer Research Center, Shahid Beheshti University of Medical sciences, Tehran, Iran

Correspondence

Omid Asbaghi, Cancer Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran. Email: omid.asbaghi@gmail.com

Mohammad Ali Goudarzi, Shahrekord Branch, Islamic Azad University, Shahrekord, Iran. Email: goudarzi.vet@gmail.com

Abstract

Purslane (Portulaca oleracea L.) is a herbal remedy with wide range of pharmaceutic properties. Although the beneficial effect of purslane on the treatment of Type 2 Diabetes Mellitus (T2DM) has been shown, there is an inconsistency among the results of previous studies. Therefore, this study is aimed at conducting a systematic review and meta-analysis on the effect of purslane on glycemic profile and oxidative stress markers. A systematic search was performed in the Scopus, Web of science, PubMed and the Cochrane Library to find articles related to the effect of the purslane on Malondialdehyde (MDA) and Total Antioxidant Capacity (TAC), Fasting Blood Sugar (FBS), Hemoglobin A1c (HbA1c), insulin resistance, Homeostatic Model Assessment for Insulin Resistance (HOMA-IR) up to September 2022. Among the 611 initial studies that were identified from searching electronic databases, 16 Randomized Clinical Trials (RCTs) involving 1122 participants (557 cases and 565 controls) were included for data analysis. The results of random-effects modeling demonstrated that purslane consumption significantly reduced FBS (p < .001), MDA (p < .001) and increased TAC (p < .001). However, purslane consumption did not affect HbA1c (p < .109), fasting insulin (p = .298) and HOMA-IR (p = .382). Meta-analyses were performed using both the random- and fixed-effects model where appropriate, and l^2 index was used

This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.

 $\ensuremath{\mathbb C}$ 2023 The Authors. Food Science & Nutrition published by Wiley Periodicals LLC.

²Department of Nutrition, School of Medical Sciences and Technologies, Islamic Azad University, Science and Research Branch, Tehran, Iran

³Nutrition Research Center, Department of Community Nutrition, Faculty of Nutrition and Food Science, Tabriz University of Medical Sciences, Tabriz, Iran

⁴Nutrition Department, Faculty of Health and Nutrition, Lorestan University of Medical Sciences, Khoramabad, Iran

to evaluate the heterogeneity. This meta-analysis study suggests that purslane has beneficial effects on oxidative stress markers and glycemic parameter. Therefore, it may be a promising adjuvant therapy in T2DM because of its benefits and negligible adverse effects.

KEYWORDS

glycemic, meta-analysis, oxidative stress, purslane, systematic review

1 | INTRODUCTION

Diabetes is a common metabolic disease that is characterized by prolonged hyperglycemia and abnormality in protein and lipid metabolism (DeFronzo et al., 2015). The prevalence of diabetes is rising globally and by 2030, there will have been over 360 million patients (Zheng et al., 2018). Common diabetes health complications are neuropathy, nephropathy, retinopathy, and cardiovascular disease (CVD) (Stolar, 2010). Additionally, one of the major problems with managing diabetes is the high expense of therapy (Domeikiene et al., 2014). Patients with diabetes are more likely to experience higher levels of oxidative stress due to increased generation of reactive oxygen species (ROS) and weakened antioxidant defense mechanisms (Oguntibeju, 2019). Hyperglycemia can lead to oxidative stress (Luc et al., 2019) which decreases insulin secretion (Maddux et al., 2001). Decreased oxidative stress may therefore aid in diabetes-related challenges (Piconi et al., 2003). Synthetic diabetic medications should not be taken during pregnancy due to their potential adverse effects (El-Sayed, 2011). Therefore, taking herbal antidiabetic agents could be beneficial (Asbaghi et al., 2019, 2021, 2022). Portulaca oleracea known as purslane is one of the herbs that can reduce blood glucose (Gong et al., 2009; Papoli, Pishdad, Nadjarzadeh, & Hosseinzadeh, 2019a; Wainstein et al., 2016), oxidative stress (Elahe Zakizadeh et al., 2013), and has beneficial impacts on decreasing blood total cholesterol and low-density lipoprotein (LDL) cholesterol (Papoli et al., 2019; Sabzghabaee et al., 2014; Zakizadeh et al., 2015). Purslane is a rich source of omega 3, carotene, flavonoids, glutathione, phenolic components, amino acids, tocopherol, polysaccharides, vitamin B complex and some other minerals and active biologic compounds such as dopamine and noradrenaline (Gheflati et al., 2019; Ghorbanian et al., 2019; PARVIN et al., 2013) In addition to the previously mentioned benefits, purslane has positive effects on scavenging free radicals, aiding total antioxidant capacity (TAC), treating various types of cancer and CVD (L. Liu et al., 2000; Yang et al., 2009).

Consuming 10 g of purslane seeds daily for 8 weeks had similar effects on fasting blood sugar (FBS) and serum insulin levels to taking 1500 mg of metformin daily (Esmaillzadeh et al., 2015). The leaves and seeds of purslane have additional health benefits including analgesic, neuroprotective, wound healing, and bronchodilation (Darvish Damavandi et al., 2021; Gheflati et al., 2019). Since to the best of our knowledge, there was no prior systematic review and dose-response meta-analysis investigating the effects of purslane on glycemic control and oxidative stress, this study was conducted to summarize the evidence from the literature regarding the effect of purslane intake on glycemic control and oxidative stress.

2 | MATERIALS AND METHODS

2.1 | Literature search

The Preferred Reporting Items for Systematic reviews and Meta-Analyses (PRISMA) guidelines for the development of protocols and reporting of systematic reviews and meta-analyses were conformed (Page et al., 2021). The following databases were used to find relevant Randomized Clinical Trials (RCTs) and recent systematic reviews of purslane in adults up to September 2022: PubMed, the Cochrane library, and Scopus and ISI web of science. The keywords ("Purslane" OR "Portulaca" OR "Portulaca oleracea") AND (intervention OR "Intervention Study" OR "Intervention Studies" OR "controlled trial" OR randomized OR randomized OR random OR randomly OR placebo OR "clinical trial" OR trial OR "randomized controlled trial" OR "randomized clinical trial" OR RCT OR blinded OR "double blind" OR "double blinded" OR trial OR "clinical trial" OR trials OR "Pragmatic Clinical Trial" OR "Cross-Over Studies" OR "Cross-Over" OR "Cross-Over Study" OR parallel OR "parallel study" OR "parallel trial") were used. There were no restrictions on date and language in the searches of different databases. References from review papers were manually searched to find missed studies from initial database search.

2.2 | Study selection and eligibility criteria

Two authors (AD and OA) revised the titles, abstracts, references, and full texts of related articles to select relevant studies. The inclusion criteria were: (1) adult participants >18 years taking purslane supplementations for ≥2 weeks; (2) having a control group where the only difference between the trial and control groups was the supplementation of purslane; (3) reports of purslane supplementation effects on FBS, Hemoglobin A1c (HbA1c), fasting insulin, Homeostatic Model assessment for Insulin Resistance (HOMA-IR), Total Antioxidant Capacity (TAC), and Malondialdehyde (MDA); (4) having a RCT design; and (5) purslane not being manipulated as part of a multicomponent supplement in either of the trial or control group. Trials on children, pregnant women, animals, in addition to review papers and case studies were excluded.

2.3 | Risk of bias

The quality of eligible studies was evaluated using the Cochrane risk of bias tool for RCTs. Two independent investigators (OA and NJ) used the following checklist for each included manuscript to categorize them into three groups of low, moderate, and high risk of bias; (1) sufficient sequence generation, (2) allocation concealment, (3) blinding of all procedures and staff, (4) unbiased appraisal of consequences, (5) incomplete data, (6) optional reporting of results (reporting bias), and (7) other possible sources of bias.

2.4 | Data extraction

The following data were extracted from included studies by the two authors (NJ and OA) separately: study characteristics (the first author, year of publication, country, study design, study duration, sample size in each group, intervention type and dose), participants' characteristics (sex, mean age, body mass index (BMI)), as well as the mean and standard deviation (SD) of FBS, HbA1c, fasting insulin, HOMA-IR, TAC and MDA concentrations in the pre-intervention and post-intervention phase.

2.5 | Statistical analysis

We fulfilled this meta-analysis using STATA statistical software (version 14; STATA Corp LP). Treatment effects were appointed as the weighted mean differences (WMD) and 95% confidence intervals (Cls) were distinguished using the random-effect models, following the DerSimonian and Laird methods. We calculated changes in FBS, HbA1c, fasting insulin, HOMA-IR, TAC, and MDA concentrations between the trial and control groups from baseline to the end of the intervention procedure. Pre-specified subgroup analyses were performed according to baseline FBS, HbA1c, fasting insulin, HOMA-IR, TAC and MDA, purslane dosage ($\leq 10 \text{ g/day vs.} > 10 \text{ g/day}$), duration of the intervention ($\geq 8 \text{ vs.} < 8 \text{ weeks}$), and health status of the participants (diabetic vs. non-diabetic).

Sensitivity analyses were carried out to evaluate the stability of the outcomes by eliminating one study at a time to notice the impact of individual papers on the pooled effect size. Funnel plots and Egger's regression test were applied to discern publication bias. A *p*-value of <.05 was considered statistically significant unless otherwise specified. The potential non-linear effects of purslane dose (g/day) and intervention duration (weeks) were studied applying the fractional polynomial modeling as well as administrating meta-regression to find the confounders and linear relations between the effect size and sample size, duration and intervention dosage.

2.6 | Certainty assessment

The total certainty of evidence across the studies was scored according to the Grading of Recommendations Assessment, Development, and Evaluation (GRADE) guidelines Working Group. According to the corresponding assessment criteria, the quality of the document was classified into high, moderate, low, and very low categories.

3 | RESULTS

3.1 | Study selection

We found 791 publications in Scopus (300), PubMed (236), Cochrane library (89), and ISI Web of Science (166) in the initial search. Of these, 204 articles were duplicated. Thus, a total of 587 articles were assessed for the title and abstract screening. After screening of title and abstract, 570 unrelated studies were discarded due to primary evaluation of inclusion criteria. As a result, 17 studies were retrieved for full-text review, one of which was excluded due to lack of sufficient data. Consequently, 16 RCTs (Adelnia Najafabadi et al., 2015; Darvish Damavandi et al., 2021; Dehghan et al., 2016; Delvarianzadeh et al., 2021; El-Sayed, 2011; Esmaillzadeh et al., 2015; Fakoori Jouibari et al., 2014; Farzanegi, 2014; Gheflati et al., 2019; Ghorbanian et al., 2019; Marjan Bedakhanian et al., 2013; Wainstein et al., 2016; Zakizadeh et al., 2015) were eligible for this systematic review and meta-analysis. Figure 1 shows the flow chart of the literature search.

3.2 | Study characteristics

Seventeen RCTs assessing the effects of purslane supplementation on glycemic control and oxidative stress were identified. Included studies were conducted in various countries such as Iran (n = 14) (Adelnia Najafabadi et al., 2015; Darvish Damavandi et al., 2021; Dehghan et al., 2016; Delvarianzadeh et al., 2021; Esmaillzadeh et al., 2015; Fakoori Jouibari et al., 2014; Farzanegi, 2014; Gheflati et al., 2019; Ghorbanian et al., 2019; Marjan Bedakhanian et al., 2017; Moradi et al., 2012; Papoli et al., 2019; Rafiee Vardanjani et al., 2013; Zakizadeh et al., 2015), Yemen (n = 1) (El-Sayed, 2011), and Israel (n = 1) (Wainstein et al., 2016). All Studies have a parallel design and two of them have a crossover design. Publication dates ranged from 2011 to 2021. The follow-up periods were from 4 weeks to 16 weeks. The sample sizes for the included studies ranged from 14 to 103. Five studies enrolled only females (Dehghan et al., 2016; Fakoori Jouibari et al., 2014; Farzanegi, 2014; Ghorbanian et al., 2019; Papoli et al., 2019) and the rest of included studies involved both genders (Adelnia Najafabadi et al., 2015; Darvish Damavandi et al., 2021; Delvarianzadeh et al., 2021; El-Sayed, 2011; Ahmad Esmaillzadeh et al., 2015; Gheflati et al., 2019; Marjan Bedakhanian et al., 2017; Moradi et al., 2012; Rafiee Vardanjani et al., 2013; Wainstein et al., 2016; Zakizadeh et al., 2015). Purslane, purslane and exercise, and purslane with aerobic training






FIGURE 1 Flow chart of study selection for inclusion trials in the systematic review.

were the three types of intervention administered. Eleven studies were conducted on patients with diabetes (Dehghan et al., 2016; Delvarianzadeh et al., 2021; El-Sayed, 2011; Esmaillzadeh et al., 2015; Fakoori Jouibari et al., 2014; Farzanegi, 2014; Wainstein et al., 2016; Zakizadeh et al., 2015), three studies on patients with non-alcoholic fatty liver disease (NAFLD) (Darvish Damavandi et al., 2021; Gheflati et al., 2019; Rafiee Vardanjani et al., 2013), two studies on metabolic syndrome (Marjan Bedakhanian et al., 2017; Papoli et al., 2019), one study on patients suffering from schizophrenia (Rafiee Vardanjani et al., 2013), one study on hypercholesterolemic participants (Moradi et al., 2012) and one study on non-active girls (Ghorbanian et al., 2019). The summary of the characteristics of the included studies is shown in Table 1. Results from the quality assessment are indicated in Table 2.

3.3 | Meta-analysis

3.3.1 | Effect of purslane supplementation on FBS

Overall, 13 effect sizes evaluated the effect of purslane supplementation on FBS. Pooled effect size from the random-effect model showed a significant decreasing effect of purslane supplementation on FBS (WMD: -8.05 mmol/L; 95% CI: -12.57 to -3.53, p < .001). There was significant heterogeneity between studies (l^2 = 86.1%, p < .001) (Figure 2a). However, after subgroup analysis, we observed significant effect of purslane supplementation on FBS in studies of less (WMD: -6.32 mmol/L; 95% CI: -11.92 to -0.73, p = .027) and more than 8 weeks (WMD: -9.96 mmol/L; 95% CI: -16.49 to -3.44,

ARI et al.													F	ood Scie	ence & I	Nutritior	Open Acces	<u>_</u> _\	NIL	EY-	5
ple	U U U	15	52	30	~	7	7	~	40	48	27	49	49	32	39	27	10	32	37	50	
Sample size	<u>o</u>	15	41	30	~	7	~	~	40	48	27	49	49	31	39	27	10	32	37	54	
	Control	metformin	lovastatin	control diet	control diet & Exercise	control diet	control diet	control diet & Exercise	control diet	control diet	control diet	Placebo	placebo & Aerobic Training	placebo	control diet	control diet	control diet	control diet	Placebo	control diet	
	Intervention dose (gr/day)	10	50	Ţ	7.5	7.5	7.5	7.5	10	10	10	7.5	7.5	0.18	0.06	10	1.2	10	0.3	10	
Intervention	Treatment group	purslane	purslane	purslane	purslane & Exercise	purslane	purslane	purslane & Exercise	purslane	purslane	purslane	purslane	purslane & Aerobic Training	purslane	purslane	purslane	purslane	purslane	purslane	purslane	
	g	32.27±5.2	26±4.9	NR	30.71±4.34	29.37 ± 4.55	NR	NR	NR	28.8 ± 3.9	31.08 ± 3.24	29.9 ± 7.3	29.5 ±7.2	29.1±3.6	28.57 ± 2.15	31.09 ± 3.24	28.21 ± 9.8	26.3 ± 3.72	31.83 ± 3.97	NR	
Means BMI	<u>n</u>	31.03 ± 3.8	27±3.9	NR	29.88 ± 4.34	29.01 ± 4.34	NR	NR	NR	28.99±3.9	32.77±3.63	29 ± 5	29.8±6.4	29.9 ±3.8	28.38 ± 1.79	32.77±3.63	27±2.6	28.23 ± 4.43	31.56±3.78	NR	
	S	40 ± 17.52	49 ± 11.6	45.26 ± 10.03	50.83±6.79	50.17 ± 5.34	50	50	35-65	51.4 ± 6.09	39.891 ± 8.84	50.17 ± 5.34	58.83±6.79	58.3 ± 10.8	47.8±6.5	39.81 ± 8.84	20-30	43.16 ± 8.33	46.05 ± 10.09	53.6±6.34	
Means age	<u>5</u>	40±17.52	44±9.6	43.76±10.96	51.17 ± 4.88	52.33 ± 4.08	50	50	35-65	51.4 ± 6.09	54.7 ± 9.52	52.33 ± 4.08	61.17 ± 4.88	52.4 ± 7.9	46.5±7.6	40.07±9.52	20-30	42.16 ± 5.48	46.18±9.71	53.5 ± 6.75	λ, not reporteα
	Participants	Type 2 Diabetes	Hypercholesterolemia patients	Schizophrenic Patients	Type 2 Diabetes	Type 2 Diabetes	Type 2 Diabetes	Type 2 Diabetes	Type 2 Diabetes	Type 2 Diabetes	Non-alcoholic fatty liver disease	Type 2 Diabetes	Type 2 Diabetes	Type 2 Diabetes	Metabolic Syndrome	Non-alcoholic fatty liver disease	Non-Active Girls	Metabolic syndrome	Non-alcoholic fatty liver disease	Type 2 Diabetes	e; NR, not reported; NR, not reported.
Lizi	duration (week)	œ	8	80	ω	œ	00	œ	5	5	ω	16	16	12	œ	8	80	12	12	4	up; M, Mal
	Sex	M/F (F: 10, M: 20)	M/F: 93	M/F: 60	F: 14	F: 14	F: 14	F: 14	M/F: 40	M/F: 48	M/F (F: 12, M: 42)	F: 98	F: 98	M/F (F: 22, M: 41)	M: 78	M/F (F: 48, M: 12)	F: 20	F: 64	M/F (F: 31, M: 43)	M/F (F: 51, M: 53)	tervention gro
	Country Study design	parallel, R, PC, DB	Parallel, R	parallel, R, PC, DB	parallel, R, PC	parallel, R, PC	parallel, R, PC, DB	parallel, R, PC, DB	Crossover, R, PC	Crossover, R, PC	parallel, R, PC, B	parallel, R, PC, DB	parallel, R, PC, DB	parallel, R, PC, DB	parallel, R, PC	parallel, R, PC	parallel, R, PC	parallel, R, PC	parallel, R, PC, DB	parallel, R, PC, DB	p; F, Female; IG, in
	Country	Yemen	Iran	Iran	Iran	Iran	Iran	Iran	Iran	Iran	Iran	Iran	Iran	lsrael	Iran	Iran	Iran	Iran	Iran	Iran	ntrol grou
	Study	El-Sayed (2011)	Moradi et al. (2012)	Rafiee Vardanjani et al. (2013)	Farzanegi (2014)	Farzanegi (2014)	Fakoori Jouibari et al. (2014)	Fakoori Jouibari et al. (2014)	Zakizadeh et al. (2015)	Esmaillzadeh et al. (2015)	Adelnia Najafabadi et al. (2015)	Dehghan et al. (<mark>2016</mark>)	Dehghan et al. (2016)	Wainstein et al. (2016)	Marjan Bedakhanian et al. (2017)	Gheflati et al. (2019)	Ghorbanian et al. (2019)	Papoli et al. (<mark>2019</mark>)	Darvish Damavandi et al. (2021)	Delvarianzadeh et al. (2021)	Abbreviations: CG, control group; F, Female; IG, intervention group; M, Male; NR,

TABLE 1 Characteristic of included studies in meta-analysis.

TABLE 2 Quality assessment.

Study	Random sequence generation	Allocation concealment	Selective reporting	Other sources of bias	Blinding (participants and personnel)	Blinding (outcome assessment)	Incomplete outcome data	General quality
El-Sayed (<mark>2011</mark>)	L	L	Н	L	L	U	L	Moderate
Moradi et al. (<mark>2012</mark>)	L	Н	Н	Н	Н	Н	L	Low
Rafiee Vardanjani et al. (2013)	L	Н	Н	Н	L	U	L	Low
Farzanegi (<mark>2014</mark>)	L	Н	Н	Н	Н	Н	L	Low
Fakoori Jouibari et al. (2014)	L	Н	Н	Н	L	U	L	Low
Zakizadeh et al. (<mark>2015</mark>)	L	Н	Н	L	Н	Н	L	Low
Esmaillzadeh et al. (2015)	L	L	Н	L	Н	Н	L	Low
Adelnia Najafabadi et al. (2015)	L	L	Н	L	L	Н	L	Low
Dehghan et al. (<mark>2016</mark>)	L	Н	Н	Н	L	U	L	Low
Wainstein et al. (2016)	L	L	L	L	L	U	L	
Marjan Bedakhanian et al. (2017)	L	L	Н	Н	Н	Н	L	Low
Gheflati et al. (<mark>2019</mark>)	L	L	Н	L	Н	Н	L	Low
Ghorbanian et al. (2019)	L	Н	Н	Н	Н	Н	L	Low
Papoli et al., <mark>2019</mark>)	L	L	Н	L	Н	Н	L	Low
Darvish Damavandi et al., 2021)	L	L	Η	L	L	U	L	Moderate
Delvarianzadeh et al., 2021)	L	Н	Η	Η	L	U	L	Low

Abbreviations: H, high-risk of bias; L, low-risk of bias; U, unclear-risk of bias.

p = .003). Similar significant effects were also detected in female (WMD: -15.43 mmol/L: 95% CI: -22.96 to -7.90, p < .001) and both sexes (WMD: -4.04 mmol/L; 95% CI: -7.83 to -0.25, p = .036). In addition, sub-group analysis based on dosage showed that purslane supplementation for <10 g/day had significant effect on FBS (WMD: -11.11 mmol/L; 95% CI: -18.20 to -4.02, p = .002). In addition, subgroup analysis demonstrated that purslane affected both diabetic (WMD: -13.74 mmol/L; 95% CI: -21.73 to -5.74, p = .001) and non-diabetic patients (WMD: -4.24 mmol/L; 95% CI: -7.77, -0.71, p = .018) significantly. Sub-group analysis based on baseline BMI showed that purslane supplementation had significant effect on overweight and obese subjects, respectively (WMD: -8.31 mmol/L; 95% CI: −15.34, to −1.29, p = .020) (WMD: −5.67 mmol/L; 95% CI: -8.10 to -3.24, p<.001). However, after subgroup analysis, we observed significant effect of purslane supplementation on FBS in studies of more than 100 mg/dL baseline serum FBS (WMD: -11.14 mmol/L; 95% CI: -17.28 to -5.01, p < 0.001) (Table 3).

3.3.2 | Effect of purslane on HbA1c

Two clinical trials evaluated the effect of purslane on HbA1c. Pooled effect size from random-effect model showed nonsignificant decreasing effect of purslane supplementation on HbA1c (WMD: -0.09 mmol/L; 95% Cl, -0.48 to 0.30, p = .652). There was no significant heterogeneity between studies ($l^2 = 61.2\%$, p < .109) (Figure 2b).

3.3.3 | Effect of purslane on fasting insulin

Upon combining five effects from 17 studies, nonsignificant differences in fasting insulin were seen in the intervention compared to the control group (WMD: -2.12mg/dL, 95% Cl -6.11 to 1.87, p = .298) following purslane supplementation. The studies were significantly heterogeneous ($l^2 = 86.4\%$, p < .001; Figure 2C).

3.3.4 | Effect of purslane on HOMA-IR


Four effect sizes from 17 studies were included in this metaanalysis. When compared with the control group counterparts, quantitative meta-analysis revealed that purslane supplementation had no significant influence on HOMA-IR levels in the intervention group (WMD: -0.14 mg/dL, 95% CI -0.45 to 0.17, p = .382; Figure 2d).

3.3.5 | Effect of purslane on TAC

Three effect sizes presenting data on purslane supplementation on TAC were analyzed. Quantitative meta-analysis revealed a significant weighted mean effect of purslane supplementation on TAC in the intervention group compared with the control group (WMD: 0.24 mg/dL, 95% CI 0.10 to 0.38, p < .001) (Figure 2e).

(a)	%
Study	Effect (95% CI) Weight
Moradi et al. 2012	- 4.00 (-0.23, 8.23) 10.03
Farzanegi. 2014 (a)	-39.28 (-65.86, -12.70) 2.29
Farzanegi. 2014 (b)	-33.46 (-69.68, 2.76) 1.37
Esmaillzadeh et al. 2015	0.60 (-9.44, 10.64) 7.13
Adelnia Najafabadi et al. 2015	-6.55 (-11.75, -1.35) 9.60
Dehghan et al. 2016 (a)	-20.20 (-24.33, -16.07) 10.07
Dehghan et al. 2016 (b)	-10.00 (-14.71, -5.29) 9.82
Wainstein et al. 2016	2.36 (-18.81, 23.53) 3.22
Bedakhanian et al. 2017	-3.45 (-7.61, 0.71) 10.06
Gheflati et al. 2019	-6.54 (-11.74, -1.34) 9.60
Papoli et al. 2019	-8.50 (-12.98, -4.02) 9.92
Darvish Damavandi et al. 2021	-5.00 (-8.24, -1.76) 10.40
Delvarianzadeh et al. 2021	-18.99 (-30.36, -7.62) 6.49
Overall, DL ($I^2 = 86.1\%$, p = 0.000)	-8.05 (-12.57, -3.53) 100.00
-50 0	1 50
NOTE: Weights are from random-effects model	

(b)



(c)

			%
Study		Effect (95% CI)	Weight
El-Saved. 2011		-10.90 (-15.09, -6.71)	18.87
Esmaillzadeh et al. 2015		-0.30 (-2.11, 1.51)	22.71
Wainstein et al. 2016	1 1 1	-0.10 (-4.09, 3.89)	19.25
Gheflati et al. 2019		-3.30 (-7.72, 1.12)	18.44
Darvish Damavandi et al. 2021	1 1 1	3.04 (-0.12, 6.20)	20.73
Overall, DL ($I^2 = 86.4\%$, p = 0.000)		-2.12 (-6.12, 1.87)	100.00
-20	0	20	

NOTE: Weights are from random-effects model



%)
CI) Weight	Effect (95% CI)		ły
0.61) 19.76	-0.10 (-0.81, 0.61)		naillzadeh et al. 2015
0.41) 54.93	-0.02 (-0.45, 0.41)		nstein et al. 2016
0.08) 7.69	-1.06 (-2.20, 0.08)	↓ I	flati et al. 2019
0.59) 17.63	-0.16 (-0.91, 0.59)		vish Damavandi et al. 2021
0.17) 100.00	-0.14 (-0.46, 0.17)		rall, IV ($I^2 = 0.0\%$, $p = 0.417$)
-	-0.14 (-0.46,		rall, IV ($I^2 = 0.0\%$, p = 0.417)

(e)

			%
Study		Effect (95% CI)	Weight
	I,		
Zakizadeh et al. 2015		0.28 (-7.80, 8.36)	0.03
Gheflati et al. 2019	÷.	0.11 (-0.20, 0.42)	21.65
Ghorbanian et al. 2019	+	0.28 (0.12, 0.44)	78.32
Overall, IV ($I^2 = 0.0\%$, $p = 0.634$)	◊	0.24 (0.10, 0.39)	100.00
	0	1 10	

(f)			%
Study		Effect (95% CI)	Weight
Vardanjani et al. 2013	+	-1.47 (-1.99, -0.95)	24.17
Fakoori Jouibari et al. 2014 (a)	•	-0.81 (-1.15, -0.47)	33.91
Fakoori Jouibari et al. 2014 (b)	•	-1.44 (-1.75, -1.13)	35.44
Zakizadeh et al. 2015		0.65 (-6.02, 7.32)	0.29
Gheflati et al. 2019	+ I	-5.12 (-20.15, 9.91)	0.06
Ghorbanian et al. 2019	-	-1.44 (-2.81, -0.07)	6.13
Overall, DL ($I^2 = 44.8\%$, p = 0.107)	\$	-1.23 (-1.59, -0.87)	100.00
-20		1 20	

NOTE: Weights are from random-effects model

FIGURE 2 Forest plot detailing weighted mean difference and 95% confidence intervals (CIs) for the effects of purslane consumption on A) FBS (mg/dL); B) HbA1c (%); C) Fasting insulin (µIU/mI); D) HOMA-IR; E) TAC (mmol/I) and MDA (µmol/mI).

				Heterogeneity	
	Effect size	WMD (95%CI)	p-value	p heterogeneity	l ²
Subgroup analyses of purslane on FE	3S level.				
Overall effect	13	-8.05 (-12.57, -3.53)	<.001	<.001	86.1%
Sex					
Both sexes	8	-4.04 (-7.83, -0.25)	.036	.001	70.4%
Female	5	-15.43 (-22.96, -7.90)	<.001	<.001	81.6%
Trial duration (week)					
≤8	8	-6.32 (-11.92, -0.73)	.027	<.001	78.2%
>8	5	-9.96 (-16.49, -3.44)	.003	<.001	88.4%
Intervention dose (g/day)					
≥10	6	-5.37 (-5.37, -10.96)	.059	<.001	81.4%
<10	7	-11.11 (-18.20, -4.02)	.002	<.001	87.8%
Baseline BMI (kg/m²)					
Overweight (25–29.9)	9	-8.31 (-15.34, -1.29)	.020	<.001	90.1%
Obese (≥30)	3	-5.67 (-8.10, -3.24)	<.001	.827	0.0%
Health status					
Diabetes	7	-13.74 (-21.73, -5.74)	.001	<.001	77.7%
Non-diabetes	6	-4.24 (-7.77, -0.71)	.018	.001	74.9%
Baseline serum FBS (mg/dL)					
<100	4	-3.41 (-8.39, 1.55)	.178	.001	80.7%
>100	9	-11.14 (-17.28, -5.01)	<.001	<.001	83.1%
Subgroup analyses of purslane on HI	bA1c.				
Overall effect	2	-0.09 (-0.48, 0.30)	.652	.109	61.2%
Subgroup analyses of purslane on fac	sting insulin.				
Overall effect	5	-2.12 (-6.11, 1.87)	.298	<.001	86.4%
Subgroup analyses of purslane on HG	OMA-IR level.				
Overall effect	4	-0.14 (-0.45, 0.17)	.382	.417	0.0%
Subgroup analyses of purslane on TA	AC.				
Overall effect	3	0.24 (0.10, 0.38)	.001	.634	0.0%
Subgroup analyses of purslane on M	DA.				
Overall effect	6	-1.23 (-1.59, -0.86)	<.001	.107	44.8%

Abbreviations: BMI, body mass index; CI, confidence interval; FBS, fasting blood glucose; HbA1c, hemoglobin A1c; HOMA-IR, Homeostatic Model Assessment for Insulin Resistance; MDA, malondialdehyde; TAC, total anti-oxidant capacity; WMD, weighted mean differences. Bold values indicate significant effect (*p*-value < .05).

3.3.6 | Effect of purslane on MDA

After combining six effect sizes from studies, purslane supplementation significantly reduced MDA when compared with various intervention strategies used on participants to those in control groups (WMD: -1.23 mg/L, 95% Cl -1.59 to -0.86, p < .001; Figure 2f).

3.3.7 | Dose-response analyses

Non-linear dose-response analyses did not demonstrate a significant relationship between doses and duration and changes in FBS levels

(Figures 4 and 5). In addition, Meta-regression analysis did not indicate a linear relationship between doses (Figure 6). However, results showed a linear relationship between duration and FBS (p = .012; Figure 7).

3.3.8 | Publication bias and sensitivity analyses

Food Science & Nutrition

Based on visual inspection of funnel plots and Egger's regression test, no evidence of publication bias for FBS (p = .491), fasting insulin (p = .461), HOMA-IR (p = .147), TAC (p = .747), and MDA (p = .856) was found (Figure 3a-f). Therefore, findings from the sensitivity analyses showed no significant effect of any individual study on the entire effect sizes of FBS, fasting insulin, HOMA-IR, TAC and MDA.





FIGURE 3 Funnel plots for the effect of purslane consumption on A) FBS (mg/dL); B) HbA1c (%); C) Fasting insulin (µIU/ml); D) HOMA-IR; E) TAC (mmol/l) and MDA (µmol/ml).

3.3.9 | Grading of evidence

The GRADE protocol was applied to find the certainty of the evidence (Table 4). The effect evaluation of risk of bias for all factors was downgraded with low quality for severe heterogeneity. The effect assessment of inconsistency for factors like FBS, HbA1c, fasting insulin and MDA was downgraded with low quality for serious and very serious heterogeneity. Results showed that all factors except FBS were downgraded with low quality for serious and very serious heterogeneity. The systematic review and meta-body analyses of evidence were rated as having moderate overall quality. FIGURE 4 Non-linear dose-response relations between purslane consumption and absolute mean differences. Doseresponse relations between dose (gr/day) and absolute mean differences in FBS (mg/dL).






FIGURE 5 Non-linear dose-response relations between purslane consumption and absolute mean differences. Doseresponse relations between duration of intervention (week) and absolute mean differences in FBS (mg/dL).

4 DISCUSSION

This is the first systematic review and meta-analysis that investigated the association between purslane consumption, glycemic control, and oxidative stress. This meta-analysis of 16 trials including 850 participants, showed a relationship between purslane intervention and oxidative stress. We found a significant reduction in FBS, MDA and increase in TAC after purslane consumption. However, no significant effect of purslane was observed on HbA1c, fasting insulin and HOMA-IR in overall effect size.

Subgroup analysis showed that purslane supplementation of >10 mg/day when the baseline serum FBS is >100 mg/dL has significant beneficial effect on FBS. Also, purslane appeared to be effective

on both sexes either with BMI = 25-29.9 or ≥ 30 , along the duration of less and more than 8 weeks in controlling FBS concentrations.

According to the current rise in diabetes-related mortality and morbidity around the world, (Roglic & Unwin, 2010; Shaw et al., 2010), numerous studies have reported the association between diabetes and CVD as the primary cause of death (Fox et al., 2015; Wright et al., 2020). Macrovascular and microvascular conditions accompanied by coronary heart disease, peripheral vascular diseases, stroke, cerebrovascular disease, neuropathy along with lower-extremity amputations, nephropathy, and retinopathy, are some complications associated with diabetes (Bansal et al., 2006; Gerstein & Werstuck, 2013; Gross et al., 2005; Yun et al., 2008). In addition to above mentioned comorbidities, mental




FIGURE 6 Linear dose-response relations between purslane consumption and absolute mean differences. Doseresponse relations between dose (gr/day) and absolute mean differences in FBS (mg/dL).

FIGURE 7 Linear dose-response relations between purslane consumption and absolute mean differences. Doseresponse relations between duration of intervention (week) and absolute mean differences in FBS (mg/dL).

health and cognitive functioning, as well as hepatic, digestive, and musculoskeletal systems are affected by diabetes (Lu et al., 2009). Epidemiologic, clinical, and experimental studies have drawn attention to several therapeutic effects of purslane seeds on pathologic conditions (El-Sayed, 2011; Sabzghabaee et al., 2014; Shobeiri et al., 2009). Purslane has a broad range of pharmaceutic properties including antidiabetic, neuroprotective, antiinflammatory, antioxidant, and anticancer activities (Iranshahy et al., 2017; Rahimi et al., 2019; Zhou et al., 2015). Purslane derives its benefits from polyunsaturated fatty acid and omega-3 fatty acids, vitamin E, vitamin C, beta-carotene, alkaloids, flavonoids, polysaccharide, cardiac glycosides, coumarins, and anthraquinone glycosides (PARVIN et al., 2013; Sabzghabaee et al., 2014). There is clear evidence that omega-3 fatty acids as the major components of purslane have been widely acknowledged for their significant beneficial effects on FBS (García-López et al., 2016; Khalili et al., 2021; Liu et al., 2022), HbA1C (Khalili et al., 2021), HOMA. IR (Khalili et al., 2021; Liu et al., 2022), and insulin (Liu et al., 2022). Omega-3 fatty acids have also been linked to a reduction in FBS, insulin, and HOMA-IR when taken with vitamin E (Asemi et al., 2016; Taghizadeh et al., 2016).

Although the precise mechanism underlying purslane's impact on the glycemic profile is still unclear, some mechanisms have been introduced regarding its beneficial effects including the upregulation of different protein expressions such as, glucose transporter 4 (GLUT-4), proliferator-activated receptor (PPAR- α), and PPAR- γ

Quality assessment	sment					Summary of findings	ßs	
Outcomes	Risk of bias	Inconsistency	Indirectness	Imprecision	Publication bias	Number of intervention/ control	WMD (95%CI)	Quality of evidence
FBS	Serious limitations ^a	Very serious limitations ^b	No serious limitations	No serious limitations	No serious limitations	904 (448/456)	-8.05 (-12.57, -3.53)	⊕⊕⊖⊖ Low
HbA1c	Serious limitations ^a	Serious limitations ^a Serious limitations ^c	No serious limitations	Serious limitations ^d	No serious limitations	167 (85/82)	-0.09 (-0.48, 0.30)	⊕⊕⊖⊖ Low
fasting insulin	Serious limitations ^a Very serious limitation	Very serious limitations ^e	No serious limitations	Serious limitations ^d	No serious limitations	287 (143/144)	-2.12 (-6.11, 1.87)	@OOO Very low
HOMA-IR	Serious limitations ^a	No serious limitations	No serious limitations	Serious limitations ^d	No serious limitations	287 (143/144)	-0.14 (-0.45, 0.17)	⊕⊕⊖O Low
TAC	Serious limitations ^a	Serious limitations ^a No serious limitations	No serious limitations	Serious limitations ^d	No serious limitations	154 (77/77)	0.24 (0.10, 0.38)	⊕⊕⊖O Low
MDA	Serious limitations a Serious limitations f	Serious limitations ^f	No serious limitations	Serious limitations ^d	No serious limitations	242 (121/121)	-1.23 (-1.59, -0.86)	@OOO Very low
^a The most of th	^a The most of the studies had low quality.	×.						

TABLE 4 GRADE profile: The effects of purslane supplementation on glycemic control and oxidative stress.

^bThe test for heterogeneity is significant for FBS, and the l^2 is high, 86.1%.

^cThe test for heterogeneity is significant for HbA1c, and the l^2 is high, 61.2%.

^dThe sample sizes less than 400.

 $^{\mathrm{e}}$ The test for heterogeneity is significant for fasting insulin, and the l^2 is high, 86.4%.

^tThe test for heterogeneity is significant for MDA, and the l^2 is high, 44.8%.

(Jung et al., 2021). Another mechanism which interprets cellular pathway and illustrates that HM-chromanone, as a component of purslane, is activation of the Phosphoinositide 3-kinases/ Protein kinase B (PI3K/AKT), Calcium/calmodulin-dependent protein kinase kinase β -AMP-activated protein kinase (CaMKK β -AMPK) and Glycogen synthase kinase-3 (GSK3) α/β pathways. As a result of these activations, glucose uptake and glycogen synthesis occurred in skeletal muscle cells (Park et al., 2021). Jung et al. concluded that purslane supplementation could be used to decrease blood glucose and body fat as well as to prevent and treat diabetes-related diseases and obesity by reducing weight gain (Jung et al., 2021). A review study revealed that purslane could considerably reduce blood glucose and alleviate lipid profiles in metabolic syndrome patients (Jalali & Rahbardar, 2022). Also, a systematic review of six RCTs, comprising 352 subjects investigating the effect of purslane on blood glucose and lipids showed that purslane can decrease FBS and triglycerides levels. However, it had no significant effect on plasma levels of total cholesterol, LDL, and high-density lipoprotein (HDL) cholesterol (Hadi et al., 2019). The results of our metaanalysis supports earlier systematic reviews and meta-analyses regarding the favorable benefits of purslane on glycemic profile (Hadi et al., 2019; Jalali & Rahbardar, 2022). A study on C57BL/ Ksj-db/db mice indicated that 6-week supplementation of purslane could significantly reduce the levels of blood glucose, HOMA-IR and HbA1c (Lee et al., 2020). The lack of sufficient studies on the effects of purslane on glycemic profile may be a contributing factor to the disparity between the findings of the meta-analyses addressing the effects of purslane on HOMA-IR and HbA1c.

Continuous elevated glucose levels interfere with many defense mechanisms that inhibit excessive synthesis of reactive oxygen molecules and oxidative stress. A change in the antioxidant defense system would certainly cause a considerable change in the antioxidant enzymes (Seven et al., 2004). MDA is one of the most frequently used biomarker of oxidative stress (Halliwell & Gutteridge, 1986). The extract of purslane along with its antioxidants constituents, such as omega-3 fatty acids, gallotannins, α -tocopherols, ascorbic acid, apigenin, guercetin, and kaempferol, can mitigate/ameliorate hydrogen peroxide-induced oxidative DNA damages in human lymphocytes (Behravan et al., 2011). Several investigations supported the view that α -tocopherol as a lipid-soluble vitamin acts as a lipid peroxyl radical scavenger and prohibits lipid peroxidation chain reactions in the cell membranes (Birben et al., 2012). Moreover, a large number of studies have revealed that purslane has a high omega-3 fatty acids content, which has been associated with lowering MDA and TAC (Abdollahzad et al., 2009; Badgujar et al., 2015; Boonthongkaew et al., 2021; Grabež et al., 2022). As opposed to our finding, a metaanalysis and systematic review of 10 intervention trials showed insignificant effect of purslane supplementation on MDA, TAC (Zhu et al., 2021). In vitro studies on purslane's anti-oxidant mechanisms suggested that the extract could reduce oxidative stress by altering the blood and liver antioxidant enzyme activities, which would result in higher levels of leptin/-actin and liver peroxisome proliferatoractivated receptors (PPAR) a/-actin (Chen et al., 2012).

Purslane has been widely used in traditional medicine (El-Sayed, 2011). Although none of the studies included in the current investigation reported any significant negative effects related to purslane supplementation, there are still some minor concerns about the high levels of oxalic acid concentrations which may probably lead to malabsorption of some minerals (Bataille & Fournier, 2001). Moreover, oxalic acid can increase the risk of kidney stones (Palaniswamy et al., 2004). Similar to other herbal medicines, pregnant women and children should use purslane with caution (Izzo et al., 2016).

To the best of our knowledge, no previous systematic review and meta-analysis has specifically evaluated the effect of purslane on glycemic profile and oxidative stress. A notable limitation of our meta-analysis is the low number of trials that were available for the meta-analysis which undermines the strength of the conclusion.

In conclusion, this systematic review and meta-analysis pointed out that purslane significantly lowered the plasma levels of FBS, MDA ameliorated TAC levels. However, it had no meaningful effect on HbA1c, HOMA-IR, and fasting insulin. Altogether, purslane as powder or capsule can be taken as a supplement to decrease FBS levels, which could minimize the risk of diabetes. However, further well-designed RCTs are needed to confirm the results of the current study.

ACKNOWLEDGEMENTS

None.

CONFLICT OF INTEREST STATEMENT

The authors declared that there is no conflict of interest.

DATA AVAILABILITY STATEMENT

Data will be made available on request.

ORCID

Omid Asbaghi D https://orcid.org/0000-0002-7740-4711

REFERENCES

- Abdollahzad, H., Eghtesadi, S., Nourmohammadi, I., Khadem-Ansari, M., Nejad-Gashti, H., & Esmaillzadeh, A. (2009). Effect of vitamin C supplementation on oxidative stress and lipid profiles in hemodialysis patients. *International Journal for Vitamin and Nutrition Research*, 79(5–6), 281–287. https://doi.org/10.1024/0300-9831.79.56.281
- Adelnia Najafabadi, E., Dehghani, A., Behradmanesh, S., & Najarzadeh, A. (2015). The effect of purslane seeds on fasting blood glucose and serum liver enzymes in patients with nonalcoholic fatty livers. *Iranian Journal of Diabetes and Obesity*, 7(4), 163–171.
- Asbaghi, O., Ashtary-Larky, D., Mousa, A., Rezaei Kelishadi, M., & Moosavian, S. P. (2022). The effects of soy products on cardiovascular risk factors in patients with type 2 diabetes: A systematic review and meta-analysis of clinical trials. *Advances in Nutrition*, 13(2), 455–473.
- Asbaghi, O., Fouladvand, F., Gonzalez, M. J., Aghamohammadi, V., Choghakhori, R., & Abbasnezhad, A. (2019). The effect of green tea on C-reactive protein and biomarkers of oxidative stress in patients with type 2 diabetes mellitus: A systematic review and metaanalysis. *Complementary Therapies in Medicine*, 46, 210–216.

- Asbaghi, O., Fouladvand, F., Gonzalez, M. J., Ashtary-Larky, D., Choghakhori, R., & Abbasnezhad, A. (2021). Effect of green tea on glycemic control in patients with type 2 diabetes mellitus: A systematic review and meta-analysis. Diabetes & Metabolic Syndrome: Clinical Research & Reviews, 15(1), 23–31.
- Asemi, Z., Soleimani, A., Bahmani, F., Shakeri, H., Mazroii, N., Abedi, F., Fallah, M., Mohammadi, A. A., & Esmaillzadeh, A. (2016). Effect of the omega-3 fatty acid plus vitamin E supplementation on subjective global assessment score, glucose metabolism, and lipid concentrations in chronic hemodialysis patients. *Molecular Nutrition & Food Research*, 60(2), 390–398. https://doi.org/10.1002/mnfr.201500584
- Badgujar, P. C., Pawar, N. N., Chandratre, G. A., Telang, A. G., & Sharma, A. K. (2015). Fipronil induced oxidative stress in kidney and brain of mice: Protective effect of vitamin E and vitamin C. *Pesticide Biochemistry and Physiology*, 118, 10–18. https://doi.org/10.1016/j. pestbp.2014.10.013
- Bansal, V., Kalita, J., & Misra, U. K. (2006). Diabetic neuropathy. Postgraduate Medical Journal, 82(964), 95–100. https://doi. org/10.1136/pgmj.2005.036137
- Bataille, P., & Fournier, A. (2001). Calcium supply in calcic lithiasis. Médecine et Nutrition (France).
- Behravan, J., Mosafa, F., Soudmand, N., Taghiabadi, E., Razavi, B. M., & Karimi, G. (2011). Protective effects of aqueous and ethanolic extracts of *Portulaca oleracea* L. aerial parts on H₂O₂-induced DNA damage in lymphocytes by comet assay. *Journal of Acupuncture and Meridian Studies*, 4(3), 193–197.
- Birben, E., Sahiner, U. M., Sackesen, C., Erzurum, S., & Kalayci, O. (2012). Oxidative stress and antioxidant defense. World Allergy Organization Journal, 5(1), 9–19.
- Boonthongkaew, C., Tong-Un, T., Kanpetta, Y., Chaungchot, N., Leelayuwat, C., & Leelayuwat, N. (2021). Vitamin C supplementation improves blood pressure and oxidative stress after acute exercise in patients with poorly controlled type 2 diabetes mellitus: A randomized, placebo-controlled, cross-over study. *The Chinese Journal of Physiology*, 64(1), 16-23. https://doi.org/10.4103/cjp. cjp_95_20
- Chen, B., Zhou, H., Zhao, W., Zhou, W., Yuan, Q., & Yang, G. (2012). Effects of aqueous extract of *Portulaca oleracea* L. on oxidative stress and liver, spleen leptin, PARα and FAS mRNA expression in high-fat diet induced mice. *Molecular Biology Reports*, 39(8), 7981–7988.
- Darvish Damavandi, R., Shidfar, F., Najafi, M., Janani, L., Masoodi, M., Akbari-Fakhrabadi, M., & Dehnad, A. (2021). Effect of *Portulaca oleracea* (purslane) extract on liver enzymes, lipid profile, and glycemic status in nonalcoholic fatty liver disease: A randomized, double-blind clinical trial. *Phytotherapy Research*, 35(6), 3145–3156. https://doi.org/10.1002/ptr.6972
- DeFronzo, R. A., Ferrannini, E., Groop, L., Henry, R. R., Herman, W. H., Holst, J. J., Hu, F. B., Kahn, C. R., Raz, I., Shulman, G. I., & Shulman, G. I. (2015). Type 2 diabetes mellitus. *Nature Reviews Disease Primers*, 1(1), 1–22.
- Dehghan, F., Soori, R., Gholami, K., Abolmaesoomi, M., Yusof, A., Muniandy, S., Heidarzadeh, S., Farzanegi, P., & Farzanegi, P. (2016). Purslane (*Portulaca oleracea*) seed consumption and aerobic training improves biomarkers associated with atherosclerosis in women with type 2 diabetes (T2D). *Scientific Reports*, 6(1), 1–11.
- Delvarianzadeh, M., Nafchi, A. M., Nouri, L., Khosravi, A., Bahar, A., & Ebrahimi, H. (2021). The effect of bread enriched with *Portulaca oleracea* on metabolic control indices in patients with type 2 diabetes: A parallel randomized clinical trial.
- Domeikienė, A., Vaivadaitė, J., Ivanauskienė, R., & Padaiga, Ž. (2014). Direct cost of patients with type 2 diabetes mellitus healthcare and its complications in Lithuania. *Medicina*, 50(1), 54–60.
- Elahe Zakizadeh, S. J., Faghihimani, E., Gohari, M., & Esmaillzadeh, A. (2013). The effect of purslane seeds on glycemic status and lipid profiles of type 2 diabetic patients: A randomized controlled crossover trial. *Health System Research*, 9(13), 1638–1648.

- El-Sayed, M.-I. K. (2011). Effects of Portulaca oleracea L. seeds in treatment of type-2 diabetes mellitus patients as adjunctive and alternative therapy. Journal of Ethnopharmacology, 137(1), 643–651.
- Esmaillzadeh, A., Zakizadeh, E., Faghihimani, E., Gohari, M., & Jazayeri, S. (2015). The effect of purslane seeds on glycemic status and lipid profiles of persons with type 2 diabetes: A randomized controlled cross-over clinical trial. Journal of Research in Medical Sciences: The Official Journal of Isfahan University of Medical Sciences, 20(1), 47–53.
- Fakoori Jouibari, M., Farzanegi, P., & Barari, A. (2014). The effect of 8week aerobic exercise with purslane supplementation consumption on peroxidant and antioxidants indicators in women with type 2 diabetes. *SSU_Journals*, 22(1), 928–939.
- Farzanegi, P. (2014). Impact of the synchronization of *Portulaca oleracea* and aerobic training on levels of MMP2 and MMP9 and TIMP1 in diabetic women type II. *Research in Molecular Medicine*, 2(2), 34–39.
- Fox, C. S., Golden, S. H., Anderson, C., Bray, G. A., Burke, L. E., de Boer, I. H., Deedwania, P., Eckel, R. H., Ershow, A. G., Fradkin, J., & Vafiadis, D. K. (2015). Update on prevention of cardiovascular disease in adults with type 2 diabetes mellitus in light of recent evidence: A scientific statement from the American Heart Association and the American Diabetes Association. *Diabetes Care, 38*(9), 1777–1803. https://doi.org/10.2337/dci15-0012
- García-López, S., Villanueva Arriaga, R. E., Nájera Medina, O., Rodríguez López, C. P., Figueroa-Valverde, L., Cervera, E. G., Muñozcano Skidmore, O., & Rosas-Nexticapa, M. (2016). One month of omega-3 fatty acid supplementation improves lipid profiles, glucose levels and blood pressure in overweight schoolchildren with metabolic syndrome. Journal of Pediatric Endocrinology and Metabolism, 29(10), 1143-1150. https://doi.org/10.1515/jpem-2015-0324
- Gerstein, H. C., & Werstuck, G. H. (2013). Dysglycaemia, vasculopenia, and the chronic consequences of diabetes. *The Lancet Diabetes and Endocrinology*, 1(1), 71–78. https://doi.org/10.1016/s2213 -8587(13)70025-1
- Gheflati, A., Adelnia, E., & Nadjarzadeh, A. (2019). The clinical effects of purslane (*Portulaca oleracea*) seeds on metabolic profiles in patients with nonalcoholic fatty liver disease: A randomized controlled clinical trial. *Phytotherapy Research*, 33(5), 1501–1509. https://doi. org/10.1002/ptr.6342
- Ghorbanian, B., Saberi, Y., Azali Alamdari, K., Shokrollahi, F., & Mohammadi, H. (2019). The effects of Portulaca supplementation on antioxidant biomarkers and oxidative stress in non-active girls. *Journal of Medicinal Plants*, 18(72), 255–263. https://doi. org/10.29252/jmp.4.72.255
- Gong, F., Li, F., Zhang, L., Li, J., Zhang, Z., & Wang, G. (2009). Hypoglycemic effects of crude polysaccharide from purslane. *International Journal* of *Molecular Sciences*, 10(3), 880–888.
- Grabež, M., Škrbić, R., Stojiljković, M. P., Vučić, V., Rudić Grujić, V., Jakovljević, V., Djuric, D. M., Suručić, R., Šavikin, K., Bigović, D., & Vasiljević, N. (2022). A prospective, randomized, double-blind, placebo-controlled trial of polyphenols on the outcomes of inflammatory factors and oxidative stress in patients with type 2 diabetes mellitus. *Reviews in Cardiovascular Medicine*, 23(2), 57. https://doi. org/10.31083/j.rcm2302057
- Gross, J. L., de Azevedo, M. J., Silveiro, S. P., Canani, L. S. H., Caramori, M. L., & Zelmanovitz, T. (2005). Diabetic nephropathy: Diagnosis, prevention, and treatment. *Diabetes Care*, 28(1), 164–176. https:// doi.org/10.2337/diacare.28.1.164
- Hadi, A., Pourmasoumi, M., Najafgholizadeh, A., Kafeshani, M., & Sahebkar, A. (2019). Effect of purslane on blood lipids and glucose: A systematic review and meta-analysis of randomized controlled trials. *Phytotherapy Research*, 33(1), 3–12.
- Halliwell, B., & Gutteridge, J. M. (1986). Oxygen free radicals and iron in relation to biology and medicine: Some problems and concepts. *Archives of Biochemistry and Biophysics*, 246(2), 501–514.
- Iranshahy, M., Javadi, B., Iranshahi, M., Jahanbakhsh, S. P., Mahyari, S., Hassani, F. V., & Karimi, G. (2017). A review of traditional uses,

MILEY_Food Science & Nutrition _

phytochemistry and pharmacology of Portulaca oleracea L. Journal of Ethnopharmacology, 205, 158–172.

- Izzo, A. A., Hoon-Kim, S., Radhakrishnan, R., & Williamson, E. M. (2016). A critical approach to evaluating clinical efficacy, adverse events and drug interactions of herbal remedies. *Phytotherapy Research*, 30(5), 691–700.
- Jalali, J., & Rahbardar, M. G. (2022). Ameliorative effects of Portulaca oleracea L. (purslane) on the metabolic syndrome: A review. Journal of Ethnopharmacology, 299, 115672. https://doi.org/10.1016/j. jep.2022.115672
- Jung, J. H., Hwang, S. B., Park, H. J., Jin, G.-R., & Lee, B. H. (2021). Antiobesity and antidiabetic effects of *Portulaca oleracea* powder intake in high-fat diet-induced obese C57BL/6 mice. *Evidence-Based Complementary and Alternative Medicine*, 2021, 5587848–5587811. https://doi.org/10.1155/2021/5587848
- Khalili, L., Valdes-Ramos, R., & Harbige, L. S. (2021). Effect of n-3 (Omega-3) polyunsaturated fatty acid supplementation on metabolic and inflammatory biomarkers and body weight in patients with type 2 diabetes mellitus: A systematic review and metaanalysis of RCTs. *Metabolites*, 11(11), 742.
- Lee, J. H., Park, J. E., & Han, J. S. (2020). Portulaca oleracea L. extract reduces hyperglycemia via PI3k/Akt and AMPK pathways in the skeletal muscles of C57BL/Ksj-db/db mice. Journal of Ethnopharmacology, 260, 112973. https://doi.org/10.1016/j.jep.2020.112973
- Liu, H., Wang, F., Liu, X., Xie, Y., Xia, H., Wang, S., & Sun, G. (2022). Effects of marine-derived and plant-derived omega-3 polyunsaturated fatty acids on erythrocyte fatty acid composition in type 2 diabetic patients. *Lipids in Health and Disease*, 21(1), 20. https://doi. org/10.1186/s12944-022-01630-0
- Liu, L., Howe, P., Zhou, Y. F., Xu, Z. Q., Hocart, C., & Zhan, R. (2000). Fatty acids and beta-carotene in australian purslane (*Portulaca oleracea*) varieties. *Journal of Chromatography*. A, 893(1), 207–213. https:// doi.org/10.1016/s0021-9673(00)00747-0
- Lu, F. P., Lin, K. P., & Kuo, H. K. (2009). Diabetes and the risk of multisystem aging phenotypes: A systematic review and metaanalysis. *PLoS One*, 4(1), e4144. https://doi.org/10.1371/journ al.pone.0004144
- Luc, K., Schramm-Luc, A., Guzik, T. J., & Mikolajczyk, T. P. (2019). Oxidative stress and inflammatory markers in prediabetes and diabetes. *Journal of Physiology and Pharmacology*, 70(6), 809–824. https://doi.org/10.26402/jpp.2019.6.01
- Maddux, B. A., See, W., Lawrence, J. C., Jr., Goldfine, A. L., Goldfine,
 I. D., & Evans, J. L. (2001). Protection against oxidative stress— Induced insulin resistance in rat L6 muscle cells by micromolar concentrations of α-Lipoic acid. *Diabetes*, 50(2), 404–410. https://doi. org/10.2337/diabetes.50.2.404
- Marjan Bedakhanian, M. H. E., Ghanadian, M., Askari, G., & Maracy, M. R. (2017). The effects of *Portulaca oleracea* on lipid profile, c-reactive protein, and fasting blood glucose in men with metabolic syndrome: A double-blind randomized clinical trial. *Journal of Health System Research*, 12(4), 478–483.
- Moradi, M.-T., Gatreh Samani, K., Farrokhi, E., Rafieian-Kopaei, M., & Karimi, A. (2012). The effects of purslane (*Portulaca oleracea* L.) on serum level of lipids, lipoproteins and paraoxanase 1 (PON1) activity in hypercholesterolemia patients. Life Science Journal-Acta Zhengzhou University Overseas Edition, 9(4), 5548–5552.
- Oguntibeju, O. O. (2019). Type 2 diabetes mellitus, oxidative stress and inflammation: Examining the links. *International Journal of Physiology, Pathophysiology and Pharmacology*, 11(3), 45–63.
- Page, M. J., McKenzie, J. E., Bossuyt, P. M., Boutron, I., Hoffmann, T. C., Mulrow, C. D., Shamseer, L., Tetzlaff, J. M., Akl, E. A., Brennan, S. E., & Brennan, S. E. (2021). The PRISMA 2020 statement: An updated guideline for reporting systematic reviews. *Systematic Reviews*, 10(1), 1–11.

- Palaniswamy, U. R., Bible, B. B., & McAvoy, R. J. (2004). Oxalic acid concentrations in purslane (*Portulaca oleracea* L.) is altered by the stage of harvest and the nitrate to ammonium ratios in hydroponics. *Scientia Horticulturae*, 102(2), 267–275.
- Papoli, M., Pishdad, S., Nadjarzadeh, A., & Hosseinzadeh, M. (2019). Effects of consuming purslane seed powder on indicators of metabolic syndrome in women: A randomized clinical trial. *Progress in Nutrition*, 21(1-S), 329–335. https://doi.org/10.23751/pn.v21i1-S.6210
- Park, J. E., Seo, Y., & Han, J. S. (2021). HM-chromanone, a component of Portulaca oleracea L., stimulates glucose uptake and glycogen synthesis in skeletal muscle cell. Phytomedicine, 83, 153473. https:// doi.org/10.1016/j.phymed.2021.153473
- Parvin, N., Farzane Dehkordi, S., Goudarzi, I., Nikfarjam, M., Rafieian, M., Heidarian, E., & Rafiee Vardanjani, L. (2013). Effects of Portulaca oleracea L (purslane) on psychological symptoms of chronic schizophrenic patients IN SINA hospital. Journal of Mazandaran University of Medical Sciences, 22(97), 2–10.

Piconi, L., Quagliaro, L., & Ceriello, A. (2003). Oxidative stress in diabetes.

- Rafiee Vardanjani, L. P. N., Farzane Dehkordi, S., Shahinfard, N., Morte, S., & Ansari Samani, R. (2013). The effects of *Portulaca oleracea* L (purslane) on psychologic symptoms and malondialdehyde level in schizophrenic patients. *SJKU*, 18(4), 28–34.
- Rahimi, V. B., Ajam, F., Rakhshandeh, H., & Askari, V. R. (2019). A pharmacological review on *Portulaca oleracea* L.: Focusing on antiinflammatory, anti-oxidant, immuno-modulatory and antitumor activities. *Journal of Pharmacopuncture*, 22(1), 7–15.
- Roglic, G., & Unwin, N. (2010). Mortality attributable to diabetes: Estimates for the year 2010. Diabetes Research and Clinical Practice, 87(1), 15–19. https://doi.org/10.1016/j.diabres.2009.10.006
- Sabzghabaee, A. M., Kelishadi, R., Jelokhanian, H., Asgary, S., Ghannadi, A., & Badri, S. (2014). Clinical effects of *Portulaca oleracea* seeds on dyslipidemia in obese adolescents: A triple-blinded randomized controlled trial. *Med Arch*, 68(3), 195–199. https://doi.org/10.5455/ medarh.2014.68.195-199
- Seven, A., Guzel, S., Seymen, O., Civelek, S., Bolayirli, M., Uncu, M., & Burcak, G. (2004). Effects of vitamin E supplementation on oxidative stress in streptozotocin induced diabetic rats: Investigation of liver and plasma. Yonsei Medical Journal, 45(4), 703–710. https://doi. org/10.3349/ymj.2004.45.4.703
- Shaw, J. E., Sicree, R. A., & Zimmet, P. Z. (2010). Global estimates of the prevalence of diabetes for 2010 and 2030. *Diabetes Research* and Clinical Practice, 87(1), 4–14. https://doi.org/10.1016/j.diabr es.2009.10.007
- Shobeiri, S. F., Sharei, S., Heidari, A., & Kianbakht, S. (2009). Portulaca oleracea L. in the treatment of patients with abnormal uterine bleeding: A pilot clinical trial. Phytotherapy Research, 23(10), 1411–1414. https://doi.org/10.1002/ptr.2790
- Stolar, M. (2010). Glycemic control and complications in type 2 diabetes mellitus. The American Journal of Medicine, 123(3), S3–S11.
- Taghizadeh, M., Jamilian, M., Mazloomi, M., Sanami, M., & Asemi, Z. (2016). A randomized-controlled clinical trial investigating the effect of omega-3 fatty acids and vitamin E co-supplementation on markers of insulin metabolism and lipid profiles in gestational diabetes. *Journal of Clinical Lipidology*, 10(2), 386–393. https://doi. org/10.1016/j.jacl.2015.12.017
- Wainstein, J., Landau, Z., Dayan, Y. B., Jakubowicz, D., Grothe, T., Perrinjaquet-Moccetti, T., & Boaz, M. (2016). Purslane extract and glucose homeostasis in adults with type 2 diabetes: A double-blind, placebo-controlled clinical trial of efficacy and safety. *Journal of Medicinal Food*, 19(2), 133–140.
- Wright, A. K., Suarez-Ortegon, M. F., Read, S. H., Kontopantelis, E., Buchan, I., Emsley, R., Sattar, N., Ashcroft, D. M., Wild, S. H., & Rutter, M. K. (2020). Risk factor control and cardiovascular event risk in people with type 2 diabetes in primary and secondary

prevention settings. *Circulation*, 142(20), 1925–1936. https://doi.org/10.1161/circulationaha.120.046783

- Yang, Z., Liu, C., Xiang, L., & Zheng, Y. (2009). Phenolic alkaloids as a new class of antioxidants in *Portulaca oleracea*. *Phytotherapy Research*, 23(7), 1032–1035. https://doi.org/10.1002/ptr.2742
- Yun, W. L., Rajendra Acharya, U., Venkatesh, Y. V., Chee, C., Min, L. C., & Ng, E. Y. K. (2008). Identification of different stages of diabetic retinopathy using retinal optical images. *Information Sciences*, 178(1), 106–121. https://doi.org/10.1016/j.ins.2007.07.020
- Zakizadeh, E., Faghihimani, E., Saneei, P., & Esmaillzadeh, A. (2015). The effect of purslane seeds on biomarkers of oxidative stress in diabetic patients: A randomized controlled cross-over clinical trial. International Journal of Preventive Medicine, 6, 95. https://doi. org/10.4103/2008-7802.166505
- Zheng, Y., Ley, S. H., & Hu, F. B. (2018). Global aetiology and epidemiology of type 2 diabetes mellitus and its complications. *Nature Reviews Endocrinology*, 14(2), 88–98.
- Zhou, Y.-X., Xin, H.-L., Rahman, K., Wang, S.-J., Peng, C., & Zhang, H. (2015). Portulaca oleracea L.: A review of Phytochemistry and pharmacological effects. BioMed Research international, 2015, 925631. https://doi.org/10.1155/2015/925631

Zhu, Y., Huang, Y., Santos, H. O., de Oliveira, C. V. C., Zhou, H., & Tang, N. (2021). Effects of purslane supplementation on C-reactive protein levels and biomarkers of oxidative stress as marks for metabolic syndrome: A systematic review and meta-analysis of randomized controlled trials. *Phytotherapy Research*, 35(10), 5477–5486. https://doi.org/10.1002/ptr.7182

How to cite this article: Jafari, N., Shoaibinobarian, N., Dehghani, A., Rad, A., Mirmohammadali, S. N., Alaeian, M. J., Hamedi, Y., Zamani, M., Goudarzi, M. A., & Asbaghi, O. (2023). The effects of purslane consumption on glycemic control and oxidative stress: A systematic review and dose-response meta-analysis. *Food Science & Nutrition*, 00, 1–17. https://doi.org/10.1002/fsn3.3311